Up to 30% of patients may never reach second-line therapy.
This clip dives into the ethical and clinical argument for using the most effective treatment upfront — especially in HER2+ disease with high CNS risk.
A powerful discussion on shared decision-making and not missing the window to deliver the deepest response.
Why First-Line Choice Matters More Than Ever in HER2+ mBC
You may also like
Recommended Videos
